| 引用本文:李海燕.养心氏治疗冠心病合并糖尿病患者的疗效观察[J].世界中医药,2016,(12):. |
|
| 养心氏治疗冠心病合并糖尿病患者的疗效观察 |
| Clinical Effect Observation of YangXinShi in the Treatment to Coronary Heart Disease complicated with Diabetes |
| 投稿时间：2016-11-03 |
| DOI：10.3969/j.issn.1673-7202.2016.12.048 |
| 中文关键词: 养心氏片 冠心病 糖尿病 心绞痛 糖化血红蛋白 |
| English Keywords:YangXinShi tablet Coronary heart disease Diabetes Angina pectoris HbA1c |
| 基金项目: |
|
| 摘要点击次数: 801 |
| 全文下载次数: 687 |
| 中文摘要: |
| 目的:评价养心氏片治疗冠心病合并糖尿病的临床疗效。方法：将100例冠心病合并糖尿病的患者随机分为对照组（西药治疗）和养心氏组（西药治疗+养心氏片），每组各50例，疗程为6个月。观察比较2组患者的心绞痛症状、血糖、HbA1c、hs-CRP、NT-proBNP、Hcy和不良反应。结果：治疗后，1）养心氏组心绞痛症状改善总有效率为92.00%，高于对照组的82.00%，差异有统计学意义（P<0.05）；2）养心氏组空腹血糖、餐后2 h血糖和HbA1c分别为（5.3±1.1）mmol/L、（9.2±1.8）mmol/L和（5.6±0.5）%，低于对照组的（6.1±1.5）mmol/L、（10.4±2.1）mmol/L和（6.1±0.8）%，P<0.05；3）养心氏组hs-CRP为（1.21±0.22）mg/L，低于对照组的（1.53±0.43）mg/L，P<0.05；4）养心氏组NT-proBNP为（667±145）ng/L，低于对照组的（927±136）ng/L，P<0.05；5）养心氏组Hcy为(8.64±0.47)μmol/L，高于对照组的(9.88±0.39)μmol/L，P<0.05；6）养心氏组不良反应发生率为2.00%，低于对照组的18.00%，P<0.05。结论：养心氏片联合西药治疗冠心病合并糖尿病比常规西药治疗效果更佳。 |
| English Summary: |
| To evaluate the effects of YangXinShi tablet oncoronary heart disease complicated with diabetes.Methods:A total of 100 patients who were diagnosed as coronary heart disease complicated with diabetes in the hospital were collected.All patients were randomly divided into YangXinShi group and control group，50 cases in each group.The control group on the western medicine(western medicine treatment)treatment basis and the YangXinShi group given oral administration of YangXinShi tableton the basis of the treatment in the control.After 6 months treatment，the clinical symptoms of angina pectoris，blood glucose，HbA1c，LVEF，hs-CRP，NT-proBNP，Hcy and adverse reactions of all patients were detected.Results:After treatment，1)the total effective rate of improving angina pectoris in YangXinShi group(92.00%)was significantly higher than that of in control group(82.00%)and the difference was statistically significant(P<0.05); 2)the fasting plasma glucose，two hourspostprandial glucose and HbA1c in YangXinShi group(5.3±1.1)mmol/L、(9.2±1.8)mmol/L and(5.6±0.5)% were significantly lower than that of in control group (6.1±1.5)mmol/L、(10.4±2.1)mmol/L and(6.1±0.8)%，P<0.05; 3)the hs-CRP in YangXinShi group (1.21±0.22)mg/L was significantly lower than that of in control group (1.53±0.43)mg/L,P<0.05; 4)the NT-proBNP in YangXinShi group (667±145)ng/L was significantly lower than that of in control group (927±136)ng/L，P<0.05; 5)the Hcy in YangXinShi group (8.64±0.47)μmol/L was significantly lower than that of in control group (9.88±0.39)μmol/L，P<0.05; 6)the incidence of adverse reactions in YangXinShi group(2.00%)was significantly lower than that of in control group(18.00%)，P<0.05.Conclusion:YangXinShi tablet combined with western medicineon coronary heart disease complicated with diabetes was better than the conventional western medicine treatment. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
